Jahn Michael, Korth Johannes, Dorsch Oliver, Anastasiou Olympia Evdoxia, Sorge-Hädicke Burkhard, Tyczynski Bartosz, Gäckler Anja, Witzke Oliver, Dittmer Ulf, Dolff Sebastian, Wilde Benjamin, Kribben Andreas
Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
KfH Kuratorium für Dialyse und Nierentransplantation e.V, KfH-Nierenzentrum Friesener Straße 37a, 96317 Kronach, Germany.
Vaccines (Basel). 2021 Apr 8;9(4):360. doi: 10.3390/vaccines9040360.
mRNA-based SARS-CoV-2 vaccines offer a preventive strategy against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections that is of interest in the care of patients on hemodialysis (HDP). We measured humoral immune responses in 72 HDP after standard vaccination with two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech). Antibody responses were evaluated with an anti-SARS-CoV-2 IgG ChemiLuminescent ImmunoAssay (CLIA) two weeks after the second dose. In addition, SARS-CoV-2 IgG was determined in a control of 16 healthy healthcare workers (HCW). The control group of HCW has shown a strong antibody response with a median (MD (Q1; Q3)) antibody titer of 800.0 AU/mL (520.5; 800.0). In comparison to HCW, HDP under 60 years of age responded equally (597.0 AU/mL (410.5; 800.0), = 0.051). However, the antibody responses of the HDP negatively correlated with age (r = 0.2954 < 0.0001), leading to significantly lower antibody titers in HDP over 60 years (280.0 AU/mL (45.7; 477.0), < 0.0001). To thoroughly understand the immunogenicity of the new mRNA-based vaccines in HDP, longitudinal data on the effectiveness and durability of antibody responses are needed. Modifications of immunization schedules should be considered in HDP with low or without antibody responsiveness after standard vaccination to boost immune reactivity and prolong protective effects in these vulnerable patients.
基于信使核糖核酸（mRNA）的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗提供了一种预防SARS-CoV-2感染的策略，这对于血液透析患者（HDP）的护理具有重要意义。我们在72名接受两剂基于mRNA的SARS-CoV-2疫苗BNT162b2（辉瑞-生物科技公司）标准接种的HDP中测量了体液免疫反应。在第二剂接种两周后，采用抗SARS-CoV-2 IgG化学发光免疫分析（CLIA）评估抗体反应。此外，在16名健康医护人员（HCW）的对照组中测定了SARS-CoV-2 IgG。HCW对照组显示出强烈的抗体反应，抗体滴度中位数（MD（Q1；Q3））为800.0 AU/mL（520.5；800.0）。与HCW相比，60岁以下的HDP反应相当（597.0 AU/mL（410.5；800.0），P = 0.051）。然而，HDP的抗体反应与年龄呈负相关（r = 0.2954，P < 0.0001），导致60岁以上的HDP抗体滴度显著降低（280.0 AU/mL（45.7；477.0），P < 0.0001）。为了全面了解新型基于mRNA的疫苗在HDP中的免疫原性，需要有关抗体反应有效性和持久性的纵向数据。对于标准接种后抗体反应低或无反应的HDP，应考虑调整免疫接种计划，以增强这些脆弱患者的免疫反应并延长保护作用。
